Sanofi announces changes to its Executive Committee Houman, Madeleine and Emmanuel will report to Sanofi’s CEO, Paul Hudson, and will be based in Paris, France. Brian, also reporting to Paul Hudson, will be based in Cambridge, US. For the past…
Oman Health Exhibition and Conference 2023: Pioneering Healthcare In alignment with the Oman Vision 2040 strategy that identifies thehealthcare sector as a pivotal industry for progression, the Oman Health Exhibition andConference (OHEC) is all set to, once again, drive advancements,…
Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer Johnson & Johnson (NYSE: JNJ) today announced that, based on preliminary results, its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock…
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has been made aware of an inadvertent…
AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting the supplemental New Drug…
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline…
MODERNA CLINICAL TRIAL DATA CONFIRM ITS UPDATED COVID-19 VACCINE GENERATES ROBUST IMMUNE RESPONSE IN HUMANS AGAINST WIDELY CIRCULATING VARIANTS Moderna, Inc. (NASDAQ:MRNA) today announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023 vaccination season…
Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to…
Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial Novo Nordisk today announced the headline results from the SELECT cardiovascular outcomes trial. The…
Johnson & Johnson Subsidiary to Appeal Bankruptcy Court Ruling that Deprived Talc Claimants of an Equitable and Efficient Resolution Johnson & Johnson (NYSE: JNJ) (the Company) today announced its subsidiary LTL Management LLC (LTL) will appeal the ruling by the…
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the…
Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy Pfizer Inc. (NYSE: PFE) today announced changes to its executive leadership team to further advance its aspirations to discover and develop new medicines and vaccines, with an emphasis on oncology.…